BioCryst shares surge on positive PhIIa gout data

Shares of Birmingham, AL-based BioCryst Pharmaceuticals (NASDAQ: BCRX) surged 15 percent this morning after the developer announced positive data from the interim analysis of a Phase IIa study of its experimental gout drug. Researchers said that BCX4208 demonstrated a statistically significant reduction in serum uric acid levels compared with a placebo for all three dosages used in the 21-day trial. Biocryst added that the drug appeared safe and well tolerated. "This successful first clinical...